基本信息 产品详情 公司简介 推荐产品
网站主页 化工产品目录 生物化工 生化试剂 激动剂抑制剂 3-[3-[2-(1-哌啶基)乙氧基]苯基]-5-(1H-1,2,4-三唑-5-基)-1H-吲唑盐酸盐 化合物 CC-401 Hydrochloride
  • 化合物 CC-401 Hydrochloride|T5833|TargetMol

化合物 CC-401 Hydrochloride|T5833|TargetMol

CC-401 Hydrochloride
1438391-30-0
315 1mg 起订
745 5mg 起订
1160 10mg 起订
上海 更新日期:2024-12-12

TargetMol中国(陶术生物)

VIP3年
联系人:邵小姐
手机:4008200310 拨打
邮箱:marketing@tsbiochem.com

产品详情:

中文名称:
化合物 CC-401 Hydrochloride
英文名称:
CC-401 Hydrochloride
CAS号:
1438391-30-0
品牌:
TargetMol
产地:
美国
保存条件:
Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
纯度规格:
≥95%
产品类别:
抑制剂
货号:
T5833

Product Introduction

Bioactivity

名称CC-401 Hydrochloride
描述CC-401 Hydrochloride (CC401 HCl) is a second generation ATP-competitive anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor (Ki of 25 to 50 nM.)with potential antineoplastic activity.
动物实验To assess the efficacy of JNK signaling inhibition by CC-401 in anti-angiogenic and oxaliplatin combination therapy in a mouse xenograft model, adult (8-10 weeks of age) female severe combined immunodeficient mice (C.B.17 SCID) were used.?To generate tumors, HT29 cells (1 × 10^6 cells) were injected subcutaneously into the left flank of the mice.?When the tumors reached approximately 200 mm^3, mice were divided into eight groups (eight mice per group) for treatment with bevacizumab , oxaliplatin, CC401, and the appropriate combinations of bevacizumab, oxaliplatin and CC-401.?Mice in the bevacizumab treatment group received 5 mg/kg of bevacizumab by intraperitoneal injection every 3 days for 21 days.?The oxaliplatin treatment group was injected intraperitoneally with 5 mg/kg oxaliplatin per week for 2 weeks.?The CC-401 treatment group was injected intraperitoneally 25 mg/kg for every 3 days.?The combination treatment groups received bevacizumab (every 3 days, 5 mg/kg), oxaliplatin (weekly for 2 weeks, 5 mg/kg), and CC-401 (every 3 days, 25 mg/kg).?The control group received saline intraperitoneally.?Tumor volume and body weight were measured every 3 days.?Tumor volume was calculated using the formula V = AB^2/2, where A is the largest diameter and B is the smallest diameter.?Tumor growth delay was calculated as the difference in the time for control and treated tumors to grow from 200 to 800 mm^3.?For tumor growth delay calculations, mice were continued to receive treatments till the tumor volume reached 800 mm^3.?For immunohistochemistry mice were sacrificed after treatments on day 9 for tumor processing and staining.
体外活性CC-401与化疗化合物联合在结肠癌细胞系中展现出协同作用,尽管这种协同作用并非总是特异性与低氧有关。详细分析主要针对HT29和SW620(敏感)及HCT116(不敏感)细胞系。在HT29和SW620细胞中,CC-401治疗导致敏感细胞中的DNA损伤更为显著。
体内活性在体内,通过JNK抑制增强了bevacizumab、oxaliplatin及其联合使用在HT29衍生的小鼠异种移植瘤中的效果,其中CC-401存在时的肿瘤生长延迟更为显著。最终,将一个占优势的负向JNK1构建(但不是JNK2)稳定引入HT29细胞中,使其在低氧条件下对oxaliplatin的敏感度提高,这表明JNK亚型在细胞对化疗反应中有不同的输入。
存储条件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度DMSO : 100 mg/mL (235.33 mM)
关键字CC 401 Hydrochloride | CC-401 | Inhibitor | JNK | CC401 Hydrochloride | CC 401 | CC401 | inhibit | CC-401 Hydrochloride
相关产品Astragaloside IV | Bentamapimod | (-)-Bornyl acetate | Anisomycin | TCS JNK 5a | JNK-IN-13 | (E)-Ferulic acid methyl ester | Urolithin B | SP600125 | SR-3306 | Ginsenoside Re | SKLB-163
相关库经典已知活性库 | 抗癌活性化合物库 | 已知活性化合物库 | 激酶抑制剂库 | 抗衰老化合物库 | 神经退行性疾病化合物库 | 药物功能重定位化合物库 | 疼痛相关化合物库 | 抗癌临床化合物库 | 抗癌药物库
CC401 HCl|TargetMol

公司简介

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿,致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区,已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库,以及多种类型的生化试剂产品,包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等,此外,我们还建设有CADD(计算机辅助药物设计)研究中心、药理实验室、药化合成平台三大技术中心,全方位满足客户的定制需求。 凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持,我们将有效帮助您缩短研发周期,取得更成功的结果。

成立日期 (12年)
注册资本 566.265100万人民币
员工人数 100-500人
年营业额 ¥ 1亿以上
经营模式 贸易,工厂,试剂,定制,服务
主营行业 天然产物,生化试剂,分子生物学,分子砌块,生物技术服务

化合物 CC-401 Hydrochloride相关厂家报价

  • CC-401
  • CC-401
  • 深圳市浩博世纪生物有限公司
  • 2019-11-15
  • ¥2511
内容声明
拨打电话 立即询价